Cosenza, L.C.; Zuccato, C.; Zurlo, M.; Gambari, R.; Finotti, A.
Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin. Genes 2022, 13, 1727.
https://doi.org/10.3390/genes13101727
AMA Style
Cosenza LC, Zuccato C, Zurlo M, Gambari R, Finotti A.
Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin. Genes. 2022; 13(10):1727.
https://doi.org/10.3390/genes13101727
Chicago/Turabian Style
Cosenza, Lucia Carmela, Cristina Zuccato, Matteo Zurlo, Roberto Gambari, and Alessia Finotti.
2022. "Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin" Genes 13, no. 10: 1727.
https://doi.org/10.3390/genes13101727
APA Style
Cosenza, L. C., Zuccato, C., Zurlo, M., Gambari, R., & Finotti, A.
(2022). Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin. Genes, 13(10), 1727.
https://doi.org/10.3390/genes13101727